Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fighting Cancer Using an Oncofetal Glycosaminoglycan-Binding Protein from Malaria Parasites

    Research output: Contribution to journalReviewResearchpeer-review

  • Benjamin Mordmüller
  • Mihály Sulyok
  • Diane Egger-Adam
  • Mafalda Resende
  • Willem A de Jongh
  • Mette H Jensen
  • Helle Holm Smedegaard
  • Sisse B Ditlev
  • Max Soegaard
  • Lars Poulsen
  • Charlotte Dyring
  • Carlos Lamsfus Calle
  • Annette Knoblich
  • Javier Ibáñez
  • Meral Esen
  • Philippe Deloron
  • Nicaise Ndam
  • Saadou Issifou
  • Sophie Houard
  • Randall F Howard
  • Steven G Reed
  • Odile Leroy
  • Adrian J F Luty
  • Thor G Theander
  • Peter G Kremsner
  • Ali Salanti
  • Morten A Nielsen
View graph of relations

BACKGROUND: Malaria in pregnancy has major impacts on mother and child health. To complement existing interventions, such as intermittent preventive treatment and use of impregnated bed nets, we developed a malaria vaccine candidate with the aim of reducing sequestration of asexual "blood-stage" parasites in the placenta, the major virulence mechanism.

METHODS: The vaccine candidate PAMVAC is based on a recombinant fragment of VAR2CSA, the Plasmodium falciparum protein responsible for binding to the placenta via chondroitin sulfate A (CSA). Healthy, adult malaria-naive volunteers were immunized with 3 intramuscular injections of 20 μg (n = 9) or 50 μg (n = 27) PAMVAC, adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) or in a liposomal formulation with QS21 (GLA-LSQ). Allocation was random and double blind. The vaccine was given every 4 weeks. Volunteers were observed for 6 months following last immunization.

RESULTS: All PAMVAC formulations were safe and well tolerated. A total of 262 adverse events (AEs) occurred, 94 (10 grade 2 and 2 grade 3) at least possibly related to the vaccine. No serious AEs occurred. Distribution and severity of AEs were similar in all arms. PAMVAC was immunogenic in all participants. PAMVAC-specific antibody levels were highest with PAMVAC-GLA-SE. The antibodies inhibited binding of VAR2CSA expressing P. falciparum-infected erythrocytes to CSA in a standardized functional assay.

CONCLUSIONS: PAMVAC formulated with Alhydrogel or GLA-based adjuvants was safe, well tolerated, and induced functionally active antibodies. Next, PAMVAC will be assessed in women before first pregnancies in an endemic area.

CLINICAL TRIALS REGISTRATION: EudraCT 2015-001827-21; ClinicalTrials.gov NCT02647489.

Original languageEnglish
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume69
Issue number9
Pages (from-to)1509-1516
Number of pages8
ISSN1058-4838
DOIs
Publication statusPublished - 15 Oct 2019

ID: 59420970